Differential effects of COX inhibitors against β-amyloid-induced neurotoxicity in human neuroblastoma cells

[1]  K. Hensley,et al.  The arachidonic acid 5‐lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor α activation of microglia and extends survival of G93A‐SOD1 transgenic mice , 2004, Journal of neurochemistry.

[2]  C. Lines,et al.  Rofecoxib , 2004, Neurology.

[3]  R. Veerhuis,et al.  Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-&bgr;1-42 , 2003, Neuroreport.

[4]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[5]  F. Fonnum,et al.  Discussion of the Role of the Extracellular Signal-Regulated Kinase-Phospholipase A2 Pathway in Production of Reactive Oxygen Species in Alzheimer's Disease , 2003, Neurochemical Research.

[6]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[7]  Michael J. Rowan,et al.  Amyloid-β oligomers: their production, toxicity and therapeutic inhibition , 2001 .

[8]  M. Kohno,et al.  Neuroprotective effects of non‐steroidal anti‐inflammatory drugs by direct scavenging of nitric oxide radicals , 2001, Journal of neurochemistry.

[9]  A. Raz,et al.  Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. , 2001, Biochemical pharmacology.

[10]  C. Yang,et al.  Determination of binding constant of transcription factor AP-1 and DNA. Application of inhibitors. , 2001, European journal of biochemistry.

[11]  M. Hüll,et al.  Interleukin‐1β Induces Cyclooxygenase‐2 and Prostaglandin E2 Synthesis in Human Neuroblastoma Cells , 2000 .

[12]  N. Bazan,et al.  Neuroinflammatory Signaling Upregulation in Alzheimer's Disease , 2000, Neurochemical Research.

[13]  Yuhui Liu,et al.  Sequential Treatment of SH‐SY5Y Cells with Retinoic Acid and Brain‐Derived Neurotrophic Factor Gives Rise to Fully Differentiated, Neurotrophic Factor‐Dependent, Human Neuron‐Like Cells , 2000, Journal of neurochemistry.

[14]  T. Town,et al.  Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway , 2000, Neurobiology of Aging.

[15]  X. Li,et al.  Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. , 1999, International journal of immunopharmacology.

[16]  M. Feldman,et al.  Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.

[17]  L. Horrocks,et al.  Phospholipase A2 and Its Role in Brain Tissue , 1997, Journal of neurochemistry.

[18]  K. Honn,et al.  Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: Role of 12‐lipoxygenase in regulating tumor cell survival , 1997, Journal of cellular physiology.

[19]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[20]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[21]  P. Kinnunen,et al.  Activation of phospholipase A2 by amyloid beta-peptides in vitro. , 1996, Biochemistry.

[22]  M. Mattson,et al.  Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium , 1995, Brain Research.

[23]  M. Pavani,et al.  Inhibition of tumoral cell respiration and growth by nordihydroguaiaretic acid. , 1994, Biochemical pharmacology.

[24]  M. Mattson,et al.  Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β-peptide toxicity, and attenuates free radical and calcium accumulation , 1994, Brain Research.

[25]  M. Mattson,et al.  A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Rozengurt,et al.  Preferential inhibition of platelet-derived growth factor-stimulated DNA synthesis and protein tyrosine phosphorylation by nordihydroguaiaretic acid. , 1994, The Journal of biological chemistry.

[27]  Carol A. Barnes,et al.  Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids , 1993, Neuron.

[28]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[29]  C. Cotman,et al.  β-Amyloid neurotoxicity: A discussion of in vitro findings , 1992, Neurobiology of Aging.

[30]  E. Frenkel,et al.  Characterization of human neuroblastoma cell lines established before and after therapy. , 1986, Journal of the National Cancer Institute.

[31]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[32]  R. DuBois,et al.  Cyclooxygenase-2: a therapeutic target. , 2002, Annual review of medicine.

[33]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[34]  P. Braquet,et al.  Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. , 1984, Prostaglandins, leukotrienes, and medicine.

[35]  M. Beaven,et al.  Evidence that indomethacin reversibly inhibits cell growth in the G1 phase of the cell cycle. , 1979, Biochemical pharmacology.